Clinical Trials for 3 Diseases
Algernon Pharmaceuticals has discovered new uses for many approved drugs. These are for billion dollar global disease markets. Planning has many phase II clinical trials for 3 target diseases.
Algernon Pharmaceuticals is a clinical stage pharmaceutical development company. The company focus on the areas of:
- non–alcoholic steatohepatitis (NASH)
- chronic kidney disease (CKD)
- inflammatory bowel disease (IBD).
Algernon’s key compounds identified using a drug repurposing strategy.
Saving Time and Money
A Drug Repurposing Strategy Can Save up to 8 years of Pre-Clinical Research and Multi Millions in R&D Costs.
The Company’s early research identified number of drug candidates that had already been approved for other diseases. Only drugs that approved in Russia, Ukraine and Japan chosen to avoid off-label prescription writing in US & Europe.
11 drug candidates screened in globally accepted animal models for 3 new disease areas:
- Non-alcoholic Steatohepatitis (NASH)
- Chronic Kidney Disease (“CKD”)
- Inflammatory Bowel Disease (IBD)
Initial studies showed that a number of the 11 drug candidates either performed equal to or better than the positive controls in each of the animal studies. Subsequent in vivo studies have confirmed their efficacy and as a result, Algernon is now in the planning stages to move its 3 lead compounds into Phase IIa clinical trials.
All Algernon research studies were conducted by 3rd party contract research organizations. The studies were well designed with proper positive controls, usually the currently accepted gold standard for treatment in the disease being screened.
For more information on Algernon Pharmaceuticals Inc. (AGN:CSE, BTHCF:OTC) please fill out the form below.